- Home
- EOI vs EMBC Comparison
EOI vs EMBC Comparison
Compare EOI & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOI
- EMBC
- Stock Information
- Founded
- EOI 2004
- EMBC 1924
- Country
- EOI United States
- EMBC United States
- Employees
- EOI N/A
- EMBC N/A
- Industry
- EOI Finance/Investors Services
- EMBC Medical/Dental Instruments
- Sector
- EOI Finance
- EMBC Health Care
- Exchange
- EOI Nasdaq
- EMBC Nasdaq
- Market Cap
- EOI 819.4M
- EMBC 811.2M
- IPO Year
- EOI N/A
- EMBC N/A
- Fundamental
- Price
- EOI $21.21
- EMBC $13.69
- Analyst Decision
- EOI
- EMBC Buy
- Analyst Count
- EOI 0
- EMBC 2
- Target Price
- EOI N/A
- EMBC $19.00
- AVG Volume (30 Days)
- EOI 83.6K
- EMBC 737.9K
- Earning Date
- EOI 01-01-0001
- EMBC 08-08-2025
- Dividend Yield
- EOI 7.19%
- EMBC 4.38%
- EPS Growth
- EOI N/A
- EMBC 18.26
- EPS
- EOI N/A
- EMBC 1.42
- Revenue
- EOI N/A
- EMBC $1,102,500,000.00
- Revenue This Year
- EOI N/A
- EMBC N/A
- Revenue Next Year
- EOI N/A
- EMBC N/A
- P/E Ratio
- EOI N/A
- EMBC $9.63
- Revenue Growth
- EOI N/A
- EMBC N/A
- 52 Week Low
- EOI $14.36
- EMBC $9.20
- 52 Week High
- EOI $18.88
- EMBC $21.48
- Technical
- Relative Strength Index (RSI)
- EOI 57.86
- EMBC 71.49
- Support Level
- EOI $21.00
- EMBC $9.65
- Resistance Level
- EOI $21.18
- EMBC $14.22
- Average True Range (ATR)
- EOI 0.20
- EMBC 0.57
- MACD
- EOI 0.02
- EMBC 0.38
- Stochastic Oscillator
- EOI 74.36
- EMBC 88.40
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.
About EMBC Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.